drugset / Trial / NCT03911973
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).
Timeline
- Start
- 2019-04-17
- Primary completion
- 2024-07
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gedatolisib | Small molecule | 150 mg | Intravenous |
| Subject | Gedatolisib | Small molecule | 180 mg | Intravenous |
| Subject | Talazoparib | Small molecule | 0.75 mg | Oral |
| Subject | Talazoparib | Small molecule | 1 mg | Oral |